帕拉曼奈尔对发作和患者睡眠质量的影响:一项前性多中心研究
G Bergamo1, M Fernandes1, S Maio2
1Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Epilepsy & behavior : E&B
|October 3, 2025
概括
佩拉曼奈尔 (PER) 显著改善了患者的睡眠质量,并减少了患者的失眠. 早期使用PER也导致了许多患者的发作减少和改善生活质量.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 临床药理学 临床药理学
背景情况:
- 初步研究表明,佩拉曼内尔 (PER) 可能有利于患者 (PwE) 的睡眠.
- 常常与睡眠障碍有关,影响整体生活质量.
- 了解早期PER干预对睡眠和的影响至关重要.
研究的目的:
- 评估早期添加 (PER) 在患者 (PwE) 的临床有效性.
- 评估PER对控制,睡眠质量,失眠,白天嗜睡,昼夜偏好,抑郁症状和生活质量的影响.
- 确定PER作为睡眠障碍PWE治疗的治疗选择的潜力.
主要方法:
- 一项涉及74名PWE的多中心研究,将PER作为早期的附加疗法启动.
- 标准化问卷 (ISI,PSQI,ESS,NDDI-E,MEQ,QoLIE-31) 在基线 (T0) 和六个月 (T1) 进行了管理.
- 测量结果包括发作频率,睡眠参数和生活质量指标.
主要成果:
- 59个普华永道公司完成了这项研究;45.76%的人在T1.1时实现了扣押自由.
- 在睡眠质量 (PSQI) 和失眠症状 (ISI) 中观察到显著改善.
- 生活质量 (QoLIE-31) 显著改善,特别是社会功能和感知到的幸福感.
结论:
- 佩拉曼内尔 (PER) 显示出作为患者 (PwE) 的有效治疗选择的潜力.
- 对于经历睡眠障碍和失眠的PWE来说,PER特别有益.
- 对PER的早期干预可能会对普华永道的控制和生活质量产生积极影响.
更多相关视频
10:25Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits
Published on: March 27, 2021
6.5K
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
21.0K
相关概念视频
Sedatives and Hypnotics Drugs: Miscellaneous Agents
515
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
515
Antiepileptic Drugs: Potassium Channel Activators
632
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
632
Epilepsy and Seizures: Overview
1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
REM Sleep Behavior Disorder
1.4K
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
1.4K
